ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) ...

Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in ...

New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR?)-targeting ant ...

CytomX Therapeutics shares yo-yoed this past week, surging on positive early clinical data for its colorectal cancer candidate, then retreating on investor questions about the data. Also, Eli Lilly ...

ABL Bio touts bispecific ADC gains, sets US trials for 206 and 209 Neoc Bio wins FDA clearance to begin phase 1 studies of ...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced the publication of abstracts for three poster presentations at the American Association for ...

Astellas Pharma has ended a six-year-old collaboration with CytomX Therapeutics designed to both expand the pharma giant’s pipeline of next-gen immuno-oncology treatments and generate up to $1.68 ...

Explore cancer drug resistance and its significant impact on treatment options and patient outcomes in modern cancer therapy.

Confirmed objective responses were observed at 8.6 and 10 mg/kg q3w, with a high overall disease control rate in late-line metastatic colorectal cancer. Progression-free survival estimates near 7 ...

Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispecific ...

Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based ...